PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

SGLT2 Inhibitors in Diabetic CKD: Metabolic Wins, Neutral Surrogates

SGLT2 inhibitorscanagliflozindapagliflozinempagliflozinsotagliflozinbexagliflozindiabetic chronic kidney diseasetype 2 diabetesnephrologymeta-analysiseGFRalbuminuriavolume depletion Nephrology / Renal Pharmacy

Background Information

SGLT2 inhibitors offer metabolic benefits but risk volume depletion in diabetic CKD.

Chronic kidney disease (CKD) in diabetes is linked with high cardiovascular risks. Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer potential renoprotective and metabolic benefits. SGLT2 inhibitors reduced glycated hemoglobin by 0.40%, body weight by 1.36 kg, and systolic blood pressure by 2.98 mm Hg without significant changes in estimated glomerular filtration rate (eGFR) or urinary albumin-to-creatinine ratio (UACR). They increased the risk of volume depletion-related events. SGLT2 inhibitors offer metabolic benefits in diabetic CKD, but clinical use should consider potential volume depletion risks. Long-term studies indicate cardiorenal protection. SGLT2 inhibitors provide glycemic and hemodynamic benefits in diabetic CKD, with manageable safety concerns.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Shi X, Fu K, Hu M, Li R, Li H, Xu S

Citation: Shi X, Fu K, Hu M, et al. Renoprotective effects and safety of sodium-glucose cotransporter 2 inhibitors in diabetic chronic kidney disease: A systematic review and meta-analysis. Medicine. 2026;105(40):e50957. doi:10.1097/MD.0000000000050957

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.